Good Showing For Nycomed's COPD Drug Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.